News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
709,377 Results
Type
Article (40742)
Company Profile (279)
Press Release (668355)
Multimedia
Podcasts (59)
Webinars (14)
Section
Business (205253)
Career Advice (2034)
Deals (35573)
Drug Delivery (95)
Drug Development (81374)
Employer Resources (173)
FDA (16349)
Job Trends (14962)
News (346960)
Policy (32715)
Tag
Academia (2594)
Accelerated approval (9)
Adcomms (23)
Allergies (95)
Alliances (49977)
ALS (109)
Alzheimer's disease (1449)
Antibody-drug conjugate (ADC) (154)
Approvals (16346)
Artificial intelligence (320)
Autoimmune disease (29)
Automation (18)
Bankruptcy (361)
Best Places to Work (11701)
BIOSECURE Act (19)
Biosimilars (121)
Biotechnology (200)
Bladder cancer (95)
Brain cancer (33)
Breast cancer (369)
Cancer (2888)
Cardiovascular disease (214)
Career advice (1701)
Career pathing (31)
CAR-T (188)
CDC (30)
Cell therapy (502)
Cervical cancer (22)
Clinical research (66993)
Collaboration (1034)
Company closure (3)
Compensation (686)
Complete response letters (22)
COVID-19 (2638)
CRISPR (59)
C-suite (328)
Cystic fibrosis (112)
Data (3005)
Decentralized trials (2)
Denatured (21)
Depression (62)
Diabetes (347)
Diagnostics (6533)
Digital health (24)
Diversity (9)
Diversity, equity & inclusion (46)
Drug discovery (138)
Drug pricing (121)
Drug shortages (29)
Duchenne muscular dystrophy (125)
Earnings (87645)
Editorial (40)
Employer branding (21)
Employer resources (150)
Events (114588)
Executive appointments (859)
FDA (18014)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (941)
Gene editing (134)
Generative AI (24)
Gene therapy (378)
GLP-1 (788)
Government (4518)
Grass and pollen (4)
Guidances (181)
Healthcare (19015)
Huntington's disease (30)
IgA nephropathy (39)
Immunology and inflammation (150)
Immuno-oncology (8)
Indications (39)
Infectious disease (2810)
Inflammatory bowel disease (158)
Inflation Reduction Act (10)
Influenza (63)
Intellectual property (120)
Interviews (316)
IPO (16638)
IRA (44)
Job creations (3650)
Job search strategy (1441)
Kidney cancer (13)
Labor market (52)
Layoffs (492)
Leadership (19)
Legal (7937)
Liver cancer (80)
Lung cancer (401)
Lymphoma (209)
Machine learning (11)
Management (59)
Manufacturing (387)
MASH (91)
Medical device (13573)
Medtech (13578)
Mergers & acquisitions (19655)
Metabolic disorders (852)
Multiple sclerosis (97)
NASH (16)
Neurodegenerative disease (115)
Neuropsychiatric disorders (32)
Neuroscience (2128)
NextGen: Class of 2025 (6578)
Non-profit (4525)
Now hiring (47)
Obesity (430)
Opinion (219)
Ovarian cancer (101)
Pain (106)
Pancreatic cancer (120)
Parkinson's disease (186)
Partnered (22)
Patents (297)
Patient recruitment (165)
Peanut (50)
People (57990)
Pharmaceutical (66)
Pharmacy benefit managers (21)
Phase I (20900)
Phase II (29502)
Phase III (21950)
Pipeline (1632)
Policy (198)
Postmarket research (2566)
Preclinical (8919)
Press Release (66)
Prostate cancer (141)
Psychedelics (36)
Radiopharmaceuticals (255)
Rare diseases (460)
Real estate (5945)
Recruiting (66)
Regulatory (22726)
Reports (50)
Research institute (2374)
Resumes & cover letters (351)
Rett syndrome (9)
RNA editing (8)
RSV (49)
Schizophrenia (86)
Series A (160)
Series B (111)
Service/supplier (11)
Sickle cell disease (62)
Special edition (19)
Spinal muscular atrophy (148)
Sponsored (32)
Startups (3623)
State (2)
Stomach cancer (15)
Supply chain (77)
Tariffs (57)
The Weekly (36)
Vaccines (781)
Venture capital (53)
Weight loss (259)
Women's health (47)
Worklife (16)
Date
Today (66)
Last 7 days (370)
Last 30 days (1881)
Last 365 days (31556)
2025 (16920)
2024 (35548)
2023 (40445)
2022 (51529)
2021 (56082)
2020 (54417)
2019 (46880)
2018 (35253)
2017 (32385)
2016 (31752)
2015 (37800)
2014 (31496)
2013 (26539)
2012 (28745)
2011 (29412)
2010 (27444)
Location
Africa (727)
Alabama (61)
Alaska (7)
Arizona (243)
Arkansas (13)
Asia (38531)
Australia (6282)
California (7506)
Canada (2365)
China (678)
Colorado (325)
Connecticut (325)
Delaware (192)
Europe (83285)
Florida (1123)
Georgia (253)
Hawaii (1)
Idaho (59)
Illinois (639)
India (26)
Indiana (362)
Iowa (16)
Japan (227)
Kansas (109)
Kentucky (29)
Louisiana (15)
Maine (64)
Maryland (1031)
Massachusetts (5596)
Michigan (247)
Minnesota (458)
Mississippi (3)
Missouri (96)
Montana (28)
Nebraska (25)
Nevada (80)
New Hampshire (66)
New Jersey (2076)
New Mexico (29)
New York (2106)
North Carolina (1085)
North Dakota (8)
Northern California (3294)
Ohio (237)
Oklahoma (16)
Oregon (34)
Pennsylvania (1615)
Puerto Rico (18)
Rhode Island (36)
South America (1108)
South Carolina (35)
South Dakota (1)
Southern California (2809)
Tennessee (127)
Texas (1128)
United States (27793)
Utah (222)
Virginia (190)
Washington D.C. (72)
Washington State (644)
West Virginia (4)
Wisconsin (66)
709,377 Results for "precision ibd inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Palisade Bio’s AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit
May 2, 2025
·
4 min read
Press Releases
Vial Initiating Phase 1 Healthy Volunteer Trial of VIAL-TL1A-HLE, a Novel Subcutaneous Half-Life Extended Anti-TL1A Antibody for the Treatment of IBD and Other Inflammatory and Fibrotic Diseases
· VIAL-TL1A-HLE is a novel, subcutaneous mAb with proprietary half-life extension technology targeting TL1A for a potentially best-in-class treatment for IBD · Preclinical data support the potential for best-in-class dosing interval for patient convenience and efficacy among anti-TL1A therapies · A Phase 1 open-label study in Australia is initiating to evaluate safety, pharmacokinetics, and pharmacodynamic responses in healthy volunteers · Interim subcutaneous safety and pharmacokinetic data from healthy volunteers expected in H2 2025
June 13, 2025
·
1 min read
Opinion
Tomorrow’s Precision Therapeutics Depend on Precision Diagnostics
Only with the adoption of digital imaging and AI-powered analysis will next-generation precision oncology therapies reach their full potential and ensure no eligible patient is overlooked.
July 14, 2025
·
3 min read
·
Robert Monroe
Business
Geneoscopy Forms Scientific Advisory Board to Support Advancement of Precision Immunology Diagnostics for Inflammatory Bowel Disease (IBD)
Geneoscopy Forms Scientific Advisory Board to Support Advancement of Precision Immunology Diagnostics for Inflammatory Bowel Disease (IBD).
January 17, 2024
·
4 min read
Press Releases
Catheter Precision, Inc. Announces First Purchase Order From University Hospital in Rennes, France
July 8, 2025
·
2 min read
Press Releases
Celltrion to present six abstracts in inflammatory bowel disease (IBD) at 2025 Digestive Disease Week® (DDW)
April 28, 2025
·
16 min read
Press Releases
Catheter Precision, Inc. Receives CE Mark for LockeT
May 27, 2025
·
3 min read
Press Releases
Cytoki Pharma Highlights Data Reinforcing Therapeutic Potential of Lipidated IL-22 for IBD in Digestive Diseases and Sciences Publication
May 8, 2025
·
3 min read
Press Releases
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment
July 9, 2025
·
3 min read
Press Releases
NImmune Biopharma to Present at DDW’25 the First Ever Head-to-Head Clinical and Translational Results for Omilancor Versus Leading Anti-TL1A in IBD Showing Superiority and Complementarity
May 6, 2025
·
7 min read
1 of 70,938
Next
